D. E. Shaw & Co. Inc. increased its stake in NxStage Medical, Inc. (NASDAQ:NXTM) by 29.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 316,312 shares of the medical device company’s stock after buying an additional 71,964 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.49% of NxStage Medical worth $7,905,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Acrospire Investment Management LLC increased its position in shares of NxStage Medical by 40.6% in the third quarter. Acrospire Investment Management LLC now owns 6,578 shares of the medical device company’s stock valued at $164,000 after buying an additional 1,900 shares during the period. Teacher Retirement System of Texas increased its position in shares of NxStage Medical by 35.5% in the second quarter. Teacher Retirement System of Texas now owns 8,958 shares of the medical device company’s stock valued at $194,000 after buying an additional 2,347 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of NxStage Medical by 56.8% in the third quarter. BNP Paribas Arbitrage SA now owns 8,700 shares of the medical device company’s stock valued at $217,000 after buying an additional 3,152 shares during the period. First Mercantile Trust Co. bought a new position in shares of NxStage Medical during the third quarter valued at about $224,000. Finally, Airain ltd bought a new position in shares of NxStage Medical during the third quarter valued at about $304,000. Institutional investors own 98.73% of the company’s stock.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) traded up 0.53% during mid-day trading on Friday, reaching $28.38. 296,231 shares of the company’s stock were exchanged. The stock’s market cap is $1.84 billion. NxStage Medical, Inc. has a one year low of $13.49 and a one year high of $28.71. The company has a 50 day moving average price of $26.92 and a 200-day moving average price of $24.86.
ILLEGAL ACTIVITY WARNING: This piece of content was published by sleekmoney and is owned by of sleekmoney. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this piece of content can be accessed at http://sleekmoney.com/nxstage-medical-inc-nxtm-shares-bought-by-d-e-shaw-co-inc/1655328.html.
NXTM has been the subject of a number of recent research reports. Canaccord Genuity set a $31.00 price objective on NxStage Medical and gave the company a “buy” rating in a report on Tuesday, December 20th. Northland Securities set a $35.00 price objective on NxStage Medical and gave the company a “buy” rating in a report on Friday, December 16th. Jefferies Group LLC increased their price objective on NxStage Medical to $38.00 and gave the company a “buy” rating in a report on Monday. Finally, Zacks Investment Research downgraded NxStage Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. NxStage Medical currently has an average rating of “Buy” and an average target price of $29.67.
In other news, insider Robert S. Brown sold 42,000 shares of NxStage Medical stock in a transaction on Thursday, January 26th. The shares were sold at an average price of $26.05, for a total transaction of $1,094,100.00. Following the completion of the sale, the insider now directly owns 55,564 shares of the company’s stock, valued at approximately $1,447,442.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Winifred L. Swan sold 3,000 shares of NxStage Medical stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $25.51, for a total transaction of $76,530.00. Following the sale, the senior vice president now directly owns 14,973 shares of the company’s stock, valued at $381,961.23. The disclosure for this sale can be found here. Insiders have sold a total of 274,091 shares of company stock valued at $7,234,794 over the last ninety days. 4.70% of the stock is currently owned by insiders.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/nxstage-medical-inc-nxtm-shares-bought-by-d-e-shaw-co-inc/1655328.html
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.